Neoadjuvant Trials in ER(+) Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.
Neoadjuvant Trials in ER(+) Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.
复制标题
DOI：
10.1158/2159-8290.cd-17-0228
复制
发表时间：
2017-06
期刊：
影响因子：
28.2
通讯作者：
Arteaga CL
中科院分区：
文献类型：
--
作者：
Guerrero-Zotano AL;Arteaga CL
新辅助治疗试验为乳腺癌的药物开发和发现提供了一种极好的策略，特别是在三阴性和HER2过表达亚型中，其中病理完全缓解是长期患者获益的良好替代。然而，对于雌激素受体（ER）阳性乳腺癌，使用这种策略一直具有挑战性，因为缺乏经过验证的长期疗效替代品和大多数患有这种癌症亚型的患者的总体良好预后。我们在下文中综述了新辅助内分泌疗法对ER +/HER2阴性乳腺癌的临床益处、其在药物开发中的用途和局限性、辅助和转移试验的优先次序以及生物标志物的发现。
Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long term patient benefit. For estrogen receptor (ER)-positive breast cancers, however, use of this strategy has been challenging because of the lack of validated surrogates of long term efficacy and the overall good prognosis of the majority of patients with this cancer subtype. We review below the clinical benefits of neodjuvant endocrine therapy for ER+/HER2-negative breast cancer, its use and limitations for drug development, prioritization of adjuvant and metastatic trials, and biomarker discovery.